Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression.

Published on May 1, 2018in Oncotarget
· DOI :10.18632/ONCOTARGET.25159
Hayley Pye9
Estimated H-index: 9
(UCL: University College London),
Mohammed A. Butt9
Estimated H-index: 9
(UCL: University College London)
+ 18 AuthorsLaurence Lovat36
Estimated H-index: 36
// Hayley Pye 1, * , Mohammed Adil Butt 1, 2, * , Laura Funnell 1 , Halla W. Reinert 1 , Ignazio Puccio 1 , Saif U. Rehman Khan 1 , Savvas Saouros 3, 4 , Jared S. Marklew 3 , Ioanna Stamati 3 , Maryam Qurashi 1, 4 , Rehan Haidry 2 , Vinay Sehgal 1, 2 , Dahmane Oukrif 5 , Michael Gandy 1 , Hayley C. Whitaker 1 , Manuel Rodriguez-Justo 5 , Marco Novelli 5 , Rifat Hamoudi 1, 6 , Gokhan Yahioglu 3, 4 , Mahendra P. Deonarain 1, 3, 4 and Laurence B. Lovat 1, 2 1 Department for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK 2 Upper Gastrointestinal Service, University College London Hospitals NHS Foundation Trust, London, UK 3 Antikor BioPharma, Stevenage, UK 4 Imperial College London, London, UK 5 Department of Pathology, University College London, London, UK 6 Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, UAE * These authors contributed equally to this work Correspondence to: Hayley Pye, email: Keywords: HER2; antibody drug conjugate; photodynamic therapy; oesophageal adenocarcinoma; heterogeneity Received: January 29, 2018      Accepted: March 28, 2018      Published: May 01, 2018 ABSTRACT Early oesophageal adenocarcinoma (OA) and pre-neoplastic dysplasia may be treated with endoscopic resection and ablative techniques such as photodynamic therapy (PDT). Though effective, discrete areas of disease may be missed leading to recurrence. PDT further suffers from the side effects of off-target photosensitivity. A tumour specific and light targeted therapeutic agent with optimised pharmacokinetics could be used to destroy residual cancerous cells left behind after resection. A small molecule antibody-photosensitizer conjugate was developed targeting human epidermal growth factor receptor 2 (HER2). This was tested in an in vivo mouse model of human OA using a xenograft flank model with clinically relevant low level HER2 expression and heterogeneity. In vitro we demonstrate selective binding of the conjugate to tumour versus normal tissue. Light dependent cytotoxicity of the phototherapy agent in vitro was observed. In an in vivo OA mouse xenograft model the phototherapy agent had desirable pharmacokinetic properties for tumour uptake and blood clearance time. PDT treatment caused tumour growth arrest in all the tumours despite the tumours having a clinically defined low/negative HER2 expression level. This new phototherapy agent shows therapeutic potential for treatment of both HER2 positive and borderline/negative OA.
Figures & Tables
📖 Papers frequently viewed together
20163.15BMC Cancer
7 Authors (Kimihiro Ito, ..., Hisao Tajiri)
16 Citations
Cited By5
#1Mahendra Deonarain (Imperial College London)H-Index: 19
#2Gokhan Yahioglu (Imperial College London)H-Index: 24
Introduction: Antibody-Drug Conjugates (ADCs) have undergone a recent resurgence with 5 product approvals over the last 2 years but for those close to the field, it’s been repeated cycles of setbac...
3 CitationsSource
#1Mahendra Deonarain (Imperial College London)H-Index: 19
#1Mahendra P Deonarain (University of Hertfordshire)
Last. Quinn XueH-Index: 1
view all 2 authors...
The pharmacokinetic-pharmacodynamic relationship is extremely complex and tumour drug penetration is one key parameter influencing therapeutic efficacy. In the context of antibody-drug conjugates (ADCs), which has undergone many innovation cycles and witnessed many failures, this feature is being addressed by a number of alternative technologies. Immunoglobulin-based ADCs continue to dominate the industrial landscape, but smaller formats offer the promise of more-effective cytotoxic payload deli...
#1Marion M. Deken (LUMC: Leiden University Medical Center)H-Index: 6
#2Marta M. Kijanka (UU: Utrecht University)H-Index: 7
Last. Sabrina Oliveira (UU: Utrecht University)H-Index: 30
view all 11 authors...
Abstract Rationale A substantial number of breast cancer patients with an overexpression of the human epidermal growth factor receptor 2 (HER2) have residual disease after neoadjuvant therapy or become resistant to trastuzumab. Photodynamic therapy (PDT) using nanobodies targeted to HER2 is a promising treatment option for these patients. Here we investigate the in vitro and in vivo antitumor efficacy of HER2-targeted nanobody-photosensitizer (PS) conjugate PDT. Methods Nanobodies targeting HER2...
12 CitationsSource
#1Anine Crous (UJ: University of Johannesburg)H-Index: 5
#2Heidi Abrahamse (UJ: University of Johannesburg)H-Index: 35
Cancer stem cells (CSCs) are a leading contributor to lung cancer mortality rates. CSCs are responsible for tumor growth and recurrence through inhibition of drug-induced cell death, decreasing the effect of traditional cancer therapy and photodynamic therapy (PDT). PDT can be improved to successfully treat lung cancer by using gold nanoparticles (AuNPs), due to their size and shape, which have been shown to facilitate drug delivery and retention, along with the targeted antibody (Ab) mediated s...
2 CitationsSource
#1Sara Fernandes (IST: Instituto Superior Técnico)H-Index: 5
#2Rosa Fernandes (UC: University of Coimbra)H-Index: 28
Last. João P. C. Tomé (IST: Instituto Superior Técnico)H-Index: 52
view all 5 authors...
Photodynamic therapy (PDT) combines a photosensitizer (PS) with the physical energy of non-ionizing light to trigger cell death pathways. PDT has potential as a therapeutic modality to be used in alternative or in combination with other conventional cancer treatment protocols (e.g. surgery, chemotherapy and radiotherapy). Still, due to the lack of specificity of the current PSs to target the tumor cells, several studies have exploited their conjugation with targeting moieties. PSs conjugated wit...
14 CitationsSource